Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05218187 · ClinicalTrials.gov registry record · NA

Robotic Gait Rehabilitation in Parkinson's Disease

A NA study of Parkinson Disease and Gait Disorder, Sensorimotor, sponsored by Indiana University.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT05218187: Recruiting NA study of Parkinson Disease and Gait Disorder, Sensorimotor, sponsored by Indiana University.

NCT05218187 is a NA study of Parkinson Disease and Gait Disorder, Sensorimotor that is actively recruiting participants, run by Indiana University. The registered enrollment target is 30 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05218187, a NA study of Parkinson Disease and Gait Disorder, Sensorimotor, is actively recruiting participants, sponsored by Indiana University.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to investigate the implementation of a novel gait rehabilitation stimulus (G-EO System) that could advance current clinical practices. The goal is to establish the safety and feasibility of gait training using the G-EO System as well as investigating the impact on mobility, function, quality of life, and participatory outcomes. Research Design: We propose a single-blinded, randomized trial of electromechanically-assisted gait training using the G-EO System in patients with Parkinson's disease with gait disability. Specific Aim 1 will establish the safety and feasibility of gait training using the G-EO System. Specific Aim 2 will determine the efficacy of gait training using the G-EO System for improving mobility, function, and quality of life

Primary Outcome

Participants will be asked to walk over a 14-foot pressure mat that will capture their comfortable walking speed. Patients will be instructed to walk at their normal comfortable speed. Walking will begin 5 feet prior to the mat so that each individual walks across the mat at a consistent speed. Participants will pass over the mat 2 times and an average speed will be calculated. It will take 5 minutes to complete this test and will be performed first.

Interventions

  • DEVICE G-EO End-Effector Gait Trainer
  • OTHER Conventional Physical Therapy Treatment

Study Locations (1)

Indiana

  • IU Health Neurorehabilitation and Robotics - Indianapolis

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2022-01-10
Est. Completion 2025-12
Phase NA
Indiana University

890 total trials

What NCT05218187 shows while recruiting

NCT05218187 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which G-EO End-Effector Gait Trainer is the first listed.

NCT05218187 reports a single indexed study location in Indiana.

Frequently Asked Questions

What is clinical trial NCT05218187 about?

NCT05218187 is a clinical study titled "Robotic Gait Rehabilitation in Parkinson's Disease". The purpose of this study is to investigate the implementation of a novel gait rehabilitation stimulus (G-EO System) that could advance current clinical practices. The goal is to establish the safety and feasibility of gait training using the G-EO System as well as investigating the impact on mobili...

What is the current status of trial NCT05218187?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2022-01-10. Estimated completion is 2025-12.

What conditions does trial NCT05218187 study?

This clinical trial studies the following conditions: Parkinson Disease, Gait Disorder, Sensorimotor.

What interventions are being tested in trial NCT05218187?

The interventions under investigation include: G-EO End-Effector Gait Trainer (DEVICE), Conventional Physical Therapy Treatment (OTHER).

Who is sponsoring clinical trial NCT05218187?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05218187 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05218187's enrollment target sits among peer trials

30 209th of 297 higher than 80 of 297 other Parkinson Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05218187, the US trial registry maintained by the National Library of Medicine. NCT05218187 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.